000 01552 a2200457 4500
005 20250513112359.0
264 0 _c19970326
008 199703s 0 0 eng d
022 _a0028-3878
024 7 _a10.1212/wnl.48.2.501
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aDyck, P J
245 0 0 _aIntradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans.
_h[electronic resource]
260 _bNeurology
_cFeb 1997
300 _a501-5 p.
_bdigital
500 _aPublication Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
650 0 4 _aAdolescent
650 0 4 _aAdult
650 0 4 _aAged
650 0 4 _aFemale
650 0 4 _aHot Temperature
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aNerve Growth Factors
_xadverse effects
650 0 4 _aPain
_xchemically induced
650 0 4 _aPain Threshold
_xdrug effects
650 0 4 _aPeripheral Nervous System Diseases
_xdrug therapy
650 0 4 _aSensation Disorders
_xchemically induced
650 0 4 _aSensory Thresholds
_xdrug effects
700 1 _aPeroutka, S
700 1 _aRask, C
700 1 _aBurton, E
700 1 _aBaker, M K
700 1 _aLehman, K A
700 1 _aGillen, D A
700 1 _aHokanson, J L
700 1 _aO'Brien, P C
773 0 _tNeurology
_gvol. 48
_gno. 2
_gp. 501-5
856 4 0 _uhttps://doi.org/10.1212/wnl.48.2.501
_zAvailable from publisher's website
999 _c9029376
_d9029376